Cibc World Market Inc. lowered its position in shares of Cencora, Inc. (NYSE:COR – Free Report) by 68.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,500 shares of the company’s stock after selling 42,623 shares during the period. Cibc World Market Inc.’s holdings in Cencora were worth $5,855,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in COR. Edgestream Partners L.P. bought a new stake in shares of Cencora in the 3rd quarter worth $9,049,000. HighTower Advisors LLC lifted its holdings in shares of Cencora by 5.6% during the third quarter. HighTower Advisors LLC now owns 125,218 shares of the company’s stock valued at $37,597,000 after purchasing an additional 6,658 shares in the last quarter. Paralel Advisors LLC boosted its position in shares of Cencora by 1.1% during the third quarter. Paralel Advisors LLC now owns 7,437 shares of the company’s stock valued at $2,233,000 after buying an additional 83 shares during the last quarter. Brendel Financial Advisors LLC purchased a new stake in shares of Cencora during the third quarter valued at $2,066,000. Finally, Cardiff Park Advisors LLC bought a new stake in Cencora in the 3rd quarter worth about $734,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Cencora
In other news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares in the company, valued at $6,305,754.60. This represents a 36.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.38% of the stock is owned by company insiders.
Cencora Price Performance
Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, topping the consensus estimate of $4.58 by $0.08. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The firm had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. During the same quarter in the prior year, the business earned $3.84 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. Equities research analysts anticipate that Cencora, Inc. will post 19.58 earnings per share for the current year.
Cencora Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Friday, November 13th will be given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, November 13th. This is a positive change from Cencora’s previous quarterly dividend of $0.60. Cencora’s payout ratio is presently 14.73%.
Analyst Upgrades and Downgrades
COR has been the topic of several research analyst reports. Evercore restated an “outperform” rating and set a $350.00 target price (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Robert W. Baird lifted their price target on shares of Cencora from $373.00 to $375.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. Barclays boosted their price objective on shares of Cencora from $350.00 to $415.00 and gave the company an “overweight” rating in a report on Wednesday. Citigroup restated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Finally, Wells Fargo & Company increased their price objective on shares of Cencora from $395.00 to $400.00 and gave the company an “overweight” rating in a research report on Tuesday, November 17th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $381.00.
View Our Latest Research Report on COR
About Cencora
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
Featured Stories
- Five stocks we like better than Cencora
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
